@MartinShkreli Off the top of my head Mexiletine is the only current one but still no where near since it normalizes some mutant channel gating. Bad Side effects
A researcher turned $100,000 into $182,761 with an 83% return using Neural Networks & Hidden Markov Models on real markets. And published the exact framework for free.
Bookmark this & study it, then read the complete breakdown in the article below before someone takes it down.
The Paris Nuclear Summit just ended. 30 countries. One declaration: triple capacity by 2050.
Nobody in that room could explain how the fuel cycle actually works.
Came across this. 100% Worth your time.
https://t.co/r3mYKBtNcf
#nuclear#nuclearsummit#SMR#fintwit
Quip’s wallet layer is where the product design gets interesting.
Post-quantum security only works if users can add protection without rebuilding their entire onchain life from scratch ⚙️
That’s why the extension model matters:
keep familiar rails, upgrade the signature surface.
Good security UX is usually invisible. 🧠
@quipnetwork $QUIP
@MartinShkreli Tough disease, until they get into trials they could start with with dC/dT to help with mtDNA synthesis, other old or off label drugs that are more supportive could be metformin or like NAD or NR.
Quality > Quantity
A few green days, and our bag are already outperforming the market:
- $BRETT back to 1.1Bil (Our entry 10mil, up 30% last week)
- $MUMU back to 150mil (Our entry 10mil, up 30% last 14d)
- $PEIPEI back to 70mil (Our entry 5mil, up 50% last month)
- $NEIRO back to 130mil (Our entry 8mil, up 100%+ last week)
- $MYRO back to 120mil (Our entry 10mil, up 50% last week)
- $MAGA back to 65mil (Our entry 5m, up 120% last 14d)
And the craziest part?
October's slot is STILL OPEN